[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Joseph S. Konowiecki, a director of Alignment Healthcare, Inc. (ALHC), reported a sale of 25,000 shares of the company's common stock on 09/09/2025 at a price of $17 per share. After the reported transaction he beneficially owned 1,127,049 shares, held directly. The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on 03/05/2025, and the Form 4 was signed by an attorney-in-fact on 09/10/2025. The disclosure is limited to this single non-derivative sale and ownership snapshot; no options, acquisitions, or other transactions are reported.

Positive

• Sale executed under a Rule 10b5-1 plan, which provides an affirmative defense and suggests the trade was pre-planned
• Detailed ownership disclosed: post-transaction beneficial ownership of 1,127,049 shares is reported

Negative

• None.

Insights

Securities Analyst

TL;DR: Director sold a small portion of holdings via a 10b5-1 plan; transaction appears routine and not clearly material.

The reported sale of 25,000 shares at $17 represents a modest disposition relative to the director's post-transaction holding of 1,127,049 shares (about 2.2% of that position). The explicit note that the sale occurred under a Rule 10b5-1 plan reduces the likelihood the trade was based on material nonpublic information.

Corporate Governance Expert

TL;DR: Use of a 10b5-1 plan demonstrates procedural compliance; the sale size is small versus total holdings.

The filing shows procedural adherence: a formal 10b5-1 plan adoption date is disclosed (03/05/2025) and the Form 4 was executed by an attorney-in-fact. From a governance perspective, these elements support transparency and pre-planned insider activity rather than opportunistic trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KONOWIECKI JOSEPH S

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		S(1)		25,000	D	$17	1,127,049	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/05/2025

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for Joseph S. Konowiecki	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ALHC director Joseph S. Konowiecki disclose on Form 4?

He disclosed a sale of 25,000 shares of Alignment Healthcare (ALHC) on 09/09/2025 at $17 per share and a post-sale beneficial ownership of 1,127,049 shares.

Was the ALHC insider sale part of a 10b5-1 plan?

Yes. The Form 4 notes the transaction was made pursuant to a Rule 10b5-1 plan adopted on 03/05/2025.

How large was the sale relative to the director's holdings in ALHC?

The sale of 25,000 shares is a small portion compared with the reported post-transaction holdings of 1,127,049 shares (about 2.2% of that position).

Who submitted the Form 4 filing for the ALHC transaction?

The Form 4 was signed by Christopher J. Joyce as attorney-in-fact for Joseph S. Konowiecki on 09/10/2025.

Does the filing report any options or derivative transactions for ALHC?

No. The Form 4 lists only a non-derivative sale of common stock and contains no derivative securities transactions.